Literature DB >> 8620574

Oxazolidonylethyl adducts to hemoglobin and DNA following nornitrogen mustard exposure.

H Thulin1, V Zorcec, D Segerbäck, A Sundwall, M Törnqvist.   

Abstract

Formation of adducts to hemoglobin (Hb) and DNA of nornitrogen mustard (NNM) was studied with the aim of developing a method for monitoring exposure to NNM. Adducts to N-terminal valines in Hb were studied by the N-alkyl Edman method using pentafluorophenyl isothiocyanate (PFPITC) as the derivatizing reagent. In preliminary studies five major Hb adducts were shown to be formed in reaction of NNM with red cell hemolysate in vitro. Following treatment with PFPITC three of these were found to be pentafluorophenylthiohydantoins (PFPTHs) of N-alkylated valines and the fourth probably originates from NNM esters in which PFPITC had reacted with the nitrogen of N-chloroethylaminoethyl. A PFPTH was found to originate from N-2-(3-oxazolidonyl)ethylvaline, Val-OZ. Val-OZ is formed in reaction, with ring closure to oxazolidone, of CO2 with the 2-chloroethylamino group in the primary valine-N adduct. Besides a few other adducts, Val-OZ was also observed in mouse Hb following injection of NNM, and also after injection of cyclophosphamide. Following reaction in vitro of NNM with DNA, three major adducts to guanine-N-7 were observed; one of them, 7-(N'-(2-chloroethyl)-2-aminoethyl]-guanine (NNMCl), was converted by carbonate to 7-(2-3-oxazolidonyl)ethyl]guanine (Gua-OZ). In mice treated with NNM, Gua-Oz was the only DNA adduct observed. Val-Oz is a chemically stable Hb adduct, potentially useful for monitoring exposures to NNM and cyclophosphamide.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8620574     DOI: 10.1016/0009-2797(95)03674-1

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  2 in total

1.  Validation of urinary excretion of cyclophosphamide as a biomarker of exposure by studying its renal clearance at high and low plasma concentrations in cancer patients.

Authors:  Maria Hedmer; Peter Höglund; Eva Cavallin-Ståhl; Maria Albin; Bo A G Jönsson
Journal:  Int Arch Occup Environ Health       Date:  2007-06-20       Impact factor: 3.015

2.  Validation of a novel procedure for quantification of the formation of phosphoramide mustard by individuals treated with cyclophosphamide.

Authors:  Hans von Stedingk; Hanjing Xie; Thomas Hatschek; Theodoros Foukakis; Andreas Rydén; Jonas Bergh; Per Rydberg
Journal:  Cancer Chemother Pharmacol       Date:  2014-07-23       Impact factor: 3.333

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.